Stockscreener 앱 받기
3.15
1.61%
0.05
시간 외 거래:
3.18
0.03
+0.95%
전일 마감가:
$3.10
열려 있는:
$3.05
하루 거래량:
54,605
Relative Volume:
0.62
시가총액:
$12.36M
수익:
$125.00K
순이익/손실:
$-14.50M
주가수익비율:
-0.6841
EPS:
-4.6043
순현금흐름:
$-14.18M
1주 성능:
+0.64%
1개월 성능:
+5.35%
6개월 성능:
-34.38%
1년 성능:
-72.50%
1일 변동 폭
$3.0401
$3.19
1주일 범위
$2.90
$3.21
52주 변동 폭
$2.52
$41.22
Imunon Inc Stock (IMNN) Company Profile
명칭
Imunon Inc
전화
(609) 896-9100
주소
997 LENOX DRIVE, LAWRENCEVILLE
Compare IMNN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMNN
Imunon Inc
|
3.15 | 12.16M | 125.00K | -14.50M | -14.18M | -4.6043 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Imunon Inc 주식(IMNN)의 최신 뉴스
Is Imunon Inc stock a good pick for beginnersWeekly Trade Report & High Return Trade Opportunity Guides - baoquankhu1.vn
Imunon (IMNN) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Imunon, Inc. (NASDAQ:IMNN) Q4 2025 Earnings Call Transcript - MSN
Guidance Update: Can Imunon Inc reach all time highs this year2026 Stock Rankings & AI Forecast Swing Trade Picks - baoquankhu1.vn
Institution Moves: Can Imunon Inc sustain earnings growth2026 Outlook & AI Forecasted Stock Moves - baoquankhu1.vn
Investment Review: Can Imunon Inc continue delivering strong returns2026 Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
HC Wainwright Brokers Increase Earnings Estimates for Imunon - Defense World
IMNN Technical Analysis & Stock Price Forecast - Intellectia AI
Imunon Earnings Call: Strong Data, Tight Cash Runway - TipRanks
Imunon Q4 Earnings Call Highlights - Defense World
IMNN PE Ratio & Valuation, Is IMNN Overvalued - Intellectia AI
Imunon, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
IMUNON reports final Phase 2 data for ovarian cancer treatment By Investing.com - Investing.com South Africa
Imunon targets ~80 OVATION 3 patients in the next 12 months as cash runway extends into H2 2026 - MSN
Imunon Inc (IMNN) Q4 2025 Earnings Call Highlights: Strategic Ad - GuruFocus
IMUNON 2025 Financial Review - AlphaStreet
IMUNON Reports 2025 Financial Results and Highlights Breakthrough Phase 3 Progress for IMNN-001 in Advanced Ovarian Cancer - Minichart
Imunon Inc’s 2025 Q4 Earnings Call: FDA Submission Delays, Shifting Trial Timelines, and Enrollment Discrepancies Highlight Contradictions - Bitget
IMUNON INC (NASDAQ:IMNN) Reports Q4 2025 Results with Focus on Phase 3 Progress for IMNN-001 - ChartMill
Earnings call transcript: Imunon Inc’s Q4 2025 shows cost discipline, clinical progress - Investing.com
IMUNON ($IMNN) Releases Q4 2025 Earnings - Quiver Quantitative
IMUNON, INC. 2025 Annual Report: Pipeline, Clinical Trials, Financials & Business Strategy Overview - Minichart
Imunon (NASDAQ: IMNN) posts strong IMNN-001 survival data but flags going concern risk - Stock Titan
Imunon Reports 2025 Financial Results And Provides Business Update - TradingView — Track All Markets
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study - The Manila Times
Imunon reports $14.5M net loss and $8.8M cash at year-end; highlights Phase 3 progress - TradingView — Track All Markets
Imunon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
IMUNON (IMNN) highlights 2025 loss reduction and strong IMNN-001 survival data - Stock Titan
IMUNON Reports 2025 Financial Results and Provides Business - GlobeNewswire
Imunon Scheduled to Announce Q4 Earnings on March 30 - Intellectia AI
Inflation Data: Can Imunon Inc sustain earnings growthPortfolio Profit Report & Verified Technical Trade Signals - baoquankhu1.vn
IMUNON reports improved survival data for ovarian cancer therapy By Investing.com - Investing.com South Africa
Imunon Inc. Expands Market Footprint Amid Strategic Deals and Financial Challenges - timothysykes.com
IMUNON's IMNN-001 Shows Continued Gains In Overall Survival In Phase 2 Ovarian Cancer Trial - RTTNews
Imunon (IMNN) Reports Promising Phase 2 OVATION 2 Trial Results - GuruFocus
IMUNON reports improved survival data for ovarian cancer therapy - investing.com
With PARP therapy, women on IMUNON lived 24.2 months longer - stocktitan.net
Aug Closing: Is Imunon Inc stock a good pick for beginners2026 Big Picture & Real-Time Volume Analysis Alerts - baoquankhu1.vn
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026 - marketscreener.com
IMUNON, Inc. Files Form 8-K with NASDAQ Listing and Company Details for March 2026 - Minichart
Imunon Expands At-The-Market Equity Offering Capacity - TipRanks
Imunon registers additional $7 million in shares under at-the-market offering - Investing.com India
Imunon registers additional $7M, raising ATM capacity to $17M - TradingView
Imunon (NASDAQ: IMNN) boosts at-the-market stock program to $17M - Stock Titan
Imunon (NASDAQ: IMNN) ups ATM program by $7M to $17M capacity - Stock Titan
S P Trends: What is the next catalyst for Imunon Inc2026 Weekly Recap & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Dividend Watch: Will Imunon Inc outperform tech stocksQuarterly Profit Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Imunon Q2 2025 Earnings Preview - MSN
Imunon declares $0.15 dividend - MSN
Signal Recap: Will Imunon Inc outperform tech stocksGold Moves & Low Risk Entry Point Guides - baoquankhu1.vn
Market Overview: Is Imunon Inc a defensive stock2025 Key Highlights & Smart Swing Trading Techniques - baoquankhu1.vn
Imunon Inc (IMNN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):